ALLUCENT Trademark

Trademark Overview


On Thursday, March 17, 2022, a trademark application was filed for ALLUCENT with the United States Patent and Trademark Office. The USPTO has given the ALLUCENT trademark a serial number of 97978604. The federal status of this trademark filing is SU - REGISTRATION REVIEW COMPLETE as of Monday, October 14, 2024. This trademark is owned by Clinical Services Corporate Operations, Inc.. The ALLUCENT trademark is filed in the Advertising, Business and Retail Services, Education & Entertainment Services, Computer & Software Services & Scientific Services, Personal, and Legal & Social Services categories with the following description:

Training and development in the field of conducting clinical trials, namely, conducting tutorials, seminars and workshops in the field of clinical trials; training in the field of computer software support, namely, conducting tutorials, seminars and workshops in the field of software support

Data management, namely, abstraction services in the nature of extracting and summarizing information from clinical trial records and collection of medical data from clinical tests and records for business purposes; Market research and business marketing consulting services in the pharmaceutical, biotechnology, medical device, and diagnostics industries; Data management, namely, the management for others of databases of patient health data

Development of regulatory compliance strategies in the field of medical research, namely, regulatory compliance consulting in the field of drug, biologic, cosmetic and medical device development

Cloud computing featuring software that allows users to collect, review, analyze and report on clinical research; technical support services, namely, installation and remote administration of software, and troubleshooting of software problems and hosted software applications, all for use in connection with medical research and product regulatory approval, environmental health, health care, and in relation to the design, research, development, and testing of new medical products and devices; cloud computing featuring software for providing telehealth, telemedicine, remote care and virtual health care services to patients; cloud computing featuring software that allows users to collect, track, retrieve, validate, summarize, statistically analyze and present data used in the areas of medical research and product regulatory approval, environmental health, health care, and in relation to the design, research, development, and testing of new medical products and devices; Cloud computing feat...
allucent

General Information


Serial Number97978604
Word MarkALLUCENT
Filing DateThursday, March 17, 2022
Status819 - SU - REGISTRATION REVIEW COMPLETE
Status DateMonday, October 14, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, August 1, 2023

Trademark Statements


Goods and ServicesTraining and development in the field of conducting clinical trials, namely, conducting tutorials, seminars and workshops in the field of clinical trials; training in the field of computer software support, namely, conducting tutorials, seminars and workshops in the field of software support
Goods and ServicesData management, namely, abstraction services in the nature of extracting and summarizing information from clinical trial records and collection of medical data from clinical tests and records for business purposes; Market research and business marketing consulting services in the pharmaceutical, biotechnology, medical device, and diagnostics industries; Data management, namely, the management for others of databases of patient health data
Goods and ServicesDevelopment of regulatory compliance strategies in the field of medical research, namely, regulatory compliance consulting in the field of drug, biologic, cosmetic and medical device development
Goods and ServicesCloud computing featuring software that allows users to collect, review, analyze and report on clinical research; technical support services, namely, installation and remote administration of software, and troubleshooting of software problems and hosted software applications, all for use in connection with medical research and product regulatory approval, environmental health, health care, and in relation to the design, research, development, and testing of new medical products and devices; cloud computing featuring software for providing telehealth, telemedicine, remote care and virtual health care services to patients; cloud computing featuring software that allows users to collect, track, retrieve, validate, summarize, statistically analyze and present data used in the areas of medical research and product regulatory approval, environmental health, health care, and in relation to the design, research, development, and testing of new medical products and devices; Cloud computing featuring software to aggregate, integrate, transfer and manage data generated from home health and remote monitoring devices and applications and health-related smart-phone applications; Cloud computing featuring software that provides integrated workflows, analytics, visualizations, and reporting features to deliver, process, analyze, elevate, and display patient-generated health data; Cloud computing featuring software that integrates remotely collected health data into databases, systems, platforms, applications, and software that inform clinical research, remote monitoring, and care management; technical consulting services, namely, evaluating the safety of pharmaceutical, medical, cosmetic and consumer devices and products in clinical development or in commercial production; Consulting services for others in the fields of design, planning, implementation and project management of clinical trials; Scientific analysis of statistical and qualitative data relating to clinical trials for pharmaceuticals, biotechnology, medical devices and diagnostics for scientific research and for the development of pharmaceutical, biotechnology, medical device and diagnostic products and methods of use of such devices and products

Classification Information


International Class035 - Advertising; business management; business administration; office functions.
US Class Codes100, 101, 102
Class Status Code6 - Active
Class Status DateWednesday, March 23, 2022
Primary Code035
First Use Anywhere DateSaturday, April 30, 2022
First Use In Commerce DateSaturday, April 30, 2022

International Class041 - Education; providing of training; entertainment; sporting and cultural activities.
US Class Codes100, 101, 107
Class Status Code6 - Active
Class Status DateWednesday, March 23, 2022
Primary Code041
First Use Anywhere DateSaturday, April 30, 2022
First Use In Commerce DateSaturday, April 30, 2022

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateWednesday, March 23, 2022
Primary Code042
First Use Anywhere DateSaturday, April 30, 2022
First Use In Commerce DateSaturday, April 30, 2022

International Class045 - Legal services; security services for the protection of property and individuals; personal and social services rendered by others to meet the needs of individuals.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateWednesday, March 23, 2022
Primary Code045
First Use Anywhere DateSaturday, April 30, 2022
First Use In Commerce DateSaturday, April 30, 2022

Trademark Owner History


Party NameClinical Services Corporate Operations, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressCary, NC 27513

Party NameClinical Services Corporate Operations, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressWaltham, MA 02452

Trademark Events


Event DateEvent Description
Monday, March 21, 2022NEW APPLICATION ENTERED
Wednesday, March 23, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, November 21, 2022LETTER OF PROTEST EVIDENCE FORWARDED
Wednesday, December 28, 2022ASSIGNED TO EXAMINER
Wednesday, January 4, 2023LETTER OF PROTEST EVIDENCE REVIEWED-NO FURTHER ACTION TAKEN
Friday, January 6, 2023NON-FINAL ACTION WRITTEN
Thursday, April 6, 2023TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, April 6, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, April 6, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, May 16, 2023FINAL REFUSAL WRITTEN
Tuesday, May 16, 2023FINAL REFUSAL E-MAILED
Tuesday, May 16, 2023NOTIFICATION OF FINAL REFUSAL EMAILED
Wednesday, June 21, 2023TEAS REQUEST FOR RECONSIDERATION RECEIVED
Thursday, June 22, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, June 23, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, August 1, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, September 26, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, March 26, 2024SOU EXTENSION 1 FILED
Tuesday, March 26, 2024SOU TEAS EXTENSION RECEIVED
Tuesday, March 26, 2024SOU EXTENSION 1 GRANTED
Friday, January 6, 2023NON-FINAL ACTION E-MAILED
Tuesday, August 1, 2023PUBLISHED FOR OPPOSITION
Friday, January 6, 2023NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, June 21, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, July 12, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Wednesday, March 27, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, April 4, 2024TEAS CHANGE OF CORRESPONDENCE RECEIVED
Thursday, April 4, 2024TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Thursday, April 4, 2024TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Thursday, April 4, 2024ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Thursday, April 11, 2024DIVISIONAL REQUEST RECEIVED
Thursday, April 11, 2024TEAS REQUEST TO DIVIDE RECEIVED
Thursday, April 11, 2024TEAS CHANGE OF CORRESPONDENCE RECEIVED
Thursday, April 11, 2024APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Thursday, April 11, 2024TEAS CHANGE OF OWNER ADDRESS RECEIVED
Thursday, April 11, 2024TEAS STATEMENT OF USE RECEIVED
Thursday, May 2, 2024CASE ASSIGNED TO INTENT TO USE PARALEGAL
Tuesday, September 17, 2024DIVISIONAL PROCESSING COMPLETE
Thursday, April 11, 2024USE AMENDMENT FILED
Tuesday, September 17, 2024STATEMENT OF USE PROCESSING COMPLETE
Monday, October 14, 2024NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Monday, October 14, 2024ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED